Salud financiera de hoja de balance de Embecta
Salud financiera controles de criterios 1/6
Embecta tiene un patrimonio de accionistas total de $-613.1M y una deuda total de $1.4B, lo que sitúa su ratio deuda-patrimonio en -222.2%. Sus activos y pasivos totales son $1.1B y $1.7B respectivamente. El BAIT de Embecta es de $325.1M, por lo que su ratio de cobertura de intereses es de 3.1. Tiene efectivo e inversiones a corto plazo que ascienden a $201.3M.
Información clave
-222.22%
Ratio deuda-patrimonio
US$1.36b
Deuda
| Ratio de cobertura de intereses | 3.1x |
| Efectivo | US$201.30m |
| Patrimonio | -US$613.10m |
| Total pasivo | US$1.68b |
| Activos totales | US$1.06b |
Actualizaciones recientes sobre salud financiera
Recent updates
EMBC: Wound Care Expansion Will Support Future Upside Despite Lower Price Targets
Analysts have trimmed their targets on Embecta by $2 to $3, citing updated expectations that align with an unchanged fair value estimate of $15, a steady discount rate of 12.33%, and consistent long term assumptions for revenue trends, profit margin, and a future P/E of about 7.9x. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed fair value estimate of $15 and implied P/E of about 7.9x as leaving room for the share price to close part of the gap if execution on the existing plan remains consistent.EMBC: Higher Discount Rate And Wound Care Expansion Will Support Future Upside
Analysts have adjusted Embecta's implied fair value price target from $16.67 to $15.00, reflecting updated views on discount rates, revenue trends, profit margins and future P/E assumptions following recent research, including price target cuts from both Mizuho and BTIG. Analyst Commentary Recent research updates point to a more cautious stance on Embecta, with the lower implied fair value aligning with trimmed price targets and more conservative assumptions around growth, profitability and P/E levels.Embecta: An Interesting Deal At An Interesting Time
Mar 19
EMBC: Future M&A And Margin Pressures Will Shape Balanced Outlook
Analysts have maintained Embecta's price target at $11.00, citing updated assumptions that include a slightly lower discount rate, softer revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Embecta is actively exploring mergers and acquisitions, with leadership emphasizing a focus on chronic care drug delivery where the company can use its manufacturing strengths and growing B2B channel (Key Developments).Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively
Feb 12
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 09Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
Feb 08EMBC: Future M&A Plans Will Test Balance Sheet And Earnings Multiple
Analysts now hold their fair value estimate for Embecta at US$11.00. The unchanged target reflects modest tweaks to assumptions around revenue growth, profit margin and future P/E that offset the slightly higher discount rate.EMBC: Future M&A Ambitions Will Heighten Risk Against Weak Earnings Multiple
Analysts have kept their fair value estimate for Embecta steady at US$11.00 while slightly adjusting underlying assumptions around discount rate, revenue growth, profit margins, and forward P/E. This reflects updated views on the company’s risk profile and earnings power without a change to the headline target.Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings
Jan 09EMBC: Medium Term Guidance Will Balance Revenue Outlook With Margin Pressures
Analysts have modestly trimmed their price target on Embecta to 11.00 dollars, reflecting slightly higher discount rate assumptions and a marginally lower anticipated future P or E multiple, partially offset by incrementally stronger expectations for revenue growth and profit margins. What's in the News Embecta issued new fiscal 2026 guidance, projecting reported revenues between 1,071 million and 1,093 million dollars, signaling confidence in its medium term growth trajectory (Key Developments).EMBC: Outlook Will Balance Stabilizing Revenues With Pressured Profit Margins Through 2026
Analysts have modestly raised their price target on Embecta to 11.00 dollars from 11.00 dollars. This reflects improved expectations for a return to positive revenue growth and a higher future earnings multiple, partially offset by a higher discount rate and slightly lower projected profit margins.US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results
Nov 28Is Now The Time To Look At Buying Embecta Corp. (NASDAQ:EMBC)?
Nov 01Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price
Sep 26Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely
Aug 28GLP-1 Partnerships Will Expand Global Healthcare Reach
The consensus price target for Embecta has been cut from $18.33 to $16.00, primarily reflecting lowered revenue growth forecasts and a declining future P/E multiple. What's in the News Embecta Corp.Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)
Jul 04Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15
May 22What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?
May 09Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price
Mar 06Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour
Feb 28New Initiatives Expected To Make Embecta More Profitable
Dec 04Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15
Nov 29At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?
Nov 07It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
Sep 24
Expanding Global Leadership In Insulin Devices Fuels Revenue Growth And Operational Efficiencies
Strengthening the base business in insulin injection devices suggests potential for stable, growing revenues as the global demographic needing these devices increases.Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
Aug 16Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next
Aug 14When Should You Buy Embecta Corp. (NASDAQ:EMBC)?
Jul 13Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
May 12Embecta's (NASDAQ:EMBC) Dividend Will Be $0.15
Feb 21Análisis de la situación financiera
Pasivos a corto plazo: EMBC tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.
Pasivo a largo plazo: EMBC tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.
Historial y análisis de deuda-patrimonio
Nivel de deuda: EMBC tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.
Reducción de la deuda: EMBC tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.
Cobertura de la deuda: La deuda de EMBC no está bien cubierta por el flujo de caja operativo (15.7%).
Cobertura de intereses: Los pagos de intereses de la deuda de EMBC están bien cubiertos por el BAIT (3.1x cobertura).
Hoja de balance
Descubre empresas con salud financiera
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/03 01:39 |
| Precio de las acciones al final del día | 2026/05/01 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/09/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Embecta Corp. está cubierta por 7 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |